Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer

Lenka Kašíková(Sotio (Czechia)), Jana Raková(Sotio (Czechia)), Michal Hensler(Sotio (Czechia)), Tereza Láníčková(Charles University), Jana Tománková(Sotio (Czechia)), Josef Pasulka(Sotio (Czechia)), Jana Drozenová(University Hospital Kralovske Vinohrady), Kateřina Mojžíšová(Sotio (Czechia)), Anna Fialová(Sotio (Czechia)), Sarka Vosahlikova(Sotio (Czechia)), Ján Laco(Charles University), Aleš Ryška(Charles University), Pavel Dundr(Charles University), Roman Kocián(Charles University), Tomáš Brtnický(Charles University), Petr Škapa(Charles University), Linda Čapková(Charles University), Marek Kovář(Czech Academy of Sciences), Jan Procházka(Czech Academy of Sciences, Institute of Molecular Genetics), Ivan Práznovec(Charles University), Vladimír Koblížek(University Hospital Hradec Králové), Alice Tašková(Charles University), Hisashi Tanaka(Cedars-Sinai Medical Center), Robert Lischke(Charles University), Fernando Casas Mendez(Charles University), J Vachtenheim(Charles University), Viola Heinzelmann‐Schwarz(University of Basel), Francis Jacob(University of Basel), Iain A. McNeish(Ovarian Cancer Action), Michal Halaška(Charles University), Lukáš Rob(Charles University), David Cibula(Charles University), Sandra Oršulić(University of California, Los Angeles), Lorenzo Galluzzi(Cornell University), Radek Špíšek(Charles University), Jitka Fučíková(Charles University)
Nature Communications
March 21, 2024
Cited by 82Open Access
Full Text

Abstract

Abstract Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8 + effector T (T EFF ) cells and TIM3 + PD1 + , hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8 + T cells. Conversely, CD8 + T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) are enriched in ICI-responsive TCF1 + PD1 + T cells. Spatial B-cell profiling identifies patterns of in situ maturation and differentiation associated with mTLSs. Moreover, B-cell depletion promotes signs of a dysfunctional CD8 + T cell compartment among tumor-infiltrating lymphocytes from freshly isolated HGSOC and NSCLC biopsies. Taken together, our data demonstrate that – at odds with NSCLC – HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that might be insufficient to preserve a ICI-sensitive TCF1 + PD1 + CD8 + T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.


Related Papers